Shanghai Haohai Biological Technology Co., Ltd. (HAOHAI BIOTEC) filed a Next Day Disclosure Return to the Hong Kong Stock Exchange on 27 April 2026, detailing the latest movements in its Hong Kong-listed H-share capital and share repurchase activity.

Key points

1. Repurchase on 27 April 2026 • Volume: 277,100 H shares • Price range: HKD 21.40–21.70 per share • Aggregate consideration: HKD 5.97 million • Purpose: Shares are earmarked for cancellation; cancellation is pending.

2. Outstanding buybacks awaiting cancellation • 23 Mar 2026: 107,200 H shares at an average HKD 22.44 • 24 Mar 2026: 14,600 H shares at an average HKD 22.76 • 27 Apr 2026: 277,100 H shares at an average HKD 21.55 Total pending cancellation: 398,900 H shares.

3. Share capital position (post-transaction, pre-cancellation) • Issued H shares (excluding treasury shares): 35.93 million • Issued A shares: 190.20 million • Treasury shares: 3.85 million A shares; no H-share treasury stock reported • Total issued shares (A + H): 226.13 million.

4. Repurchase mandate utilisation • Shareholders authorised a buyback limit of 3.91 million H shares on 10 Jun 2025. • Cumulative repurchases to date: 2.999 million H shares, equal to 7.66 % of outstanding shares at mandate date. • Remaining authority: approximately 0.91 million H shares. • In accordance with HKEX rules, HAOHAI BIOTEC is subject to a moratorium on new share issues or treasury share sales until 27 May 2026.

The company affirmed that all repurchases were executed on the Hong Kong Stock Exchange in compliance with relevant listing rules and regulatory requirements, and that no changes occurred in total issued share capital as of 27 April 2026 because the repurchased shares had not yet been cancelled.